Site Search
Google Search
search button

Breaking News:

Graham Plans to Ask FBI If It's True They Were Investigating Trump Regarding Russia Connection      - | -     White House Trying to Fix Relationship with Turkey After Trump Threatens to Devastate Their Economy      - | -     Trump Rejects Plan to Reopen Government During Negotiations      - | -     Barr Promises to Let Mueller Finish His Investigation      - | -     GOP Congressman Invokes 'The Deep State'
Pfizer Ends Research for New Alzheimer's, Parkinson's Drugs
Get Business & Technology Alerts

viewsViews 1391
7 Jan 2018 07:37 PM EST

NEW YORK (Reuters) - Pfizer Inc (PFE.N) is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease, the U.S. pharmaceutical company announced on Saturday. The company said it expects to eliminate 300 positions from the neuroscience discovery and early development programs in Andover and Cambridge, Massachusetts, and Groton, Connecticut, as it redistributes the money spent on research, according to the emailed statement. Pfizer is not making any changes to research and development funding for tanezumab, which is marketed as a treatment for joint pain from osteoarthritis, fibromyalgia treatment Lyrica, or its rare disease program.

Post Your Comment
Excellent Very Good Good Fair Poor



Recently Posted Comments
FREE
AllMediaNY AllMediaNY AllMedaiNY